Scientific article
Open access

Docetaxel-based chemotherapy in the treatment of gastric cancer

ContributorsRoth, Arnaud; Ajani, J
Published inAnnals of oncology, vol. 14 Suppl 2, p. ii41-44
Publication date2003

Docetaxel-based chemotherapy appears to have considerable promise in advanced gastric cancer. In phase II studies of single agent docetaxel, response rates (RRs) of 17% to 24% have been achieved in previously untreated patients. Importantly, RRs of 20% to 22% are seen in second-line treatment. Work by a Swiss and Italian collaborative group has shown that the combination of docetaxel 85 mg/m(2) with cisplatin 75 mg/m(2) every 3 weeks is quite active, achieving an RR of 55% and median survival of 9 months. Hematotoxicity was the main adverse event but was manageable. In other respects the docetaxel/cisplatin doublet (TC) was relatively well tolerated. The same group demonstrated that continuous infusion of 5-fluorouracil (5-FU) 300 mg/m(2) can be given on 2 weeks out of 3 to patients receiving TC. The addition of 5-FU, by this schedule, to TC (TCF) does not increase hematological toxicity, and does not compromise the tolerability of TC. An overall RR of 55% has been reported with TCF. A randomized phase II comparison of TC or TCF versus an ECF (epirubicin/cisplatin/5-FU) control arm is ongoing and should lead to a randomized phase III trial comparing TC or TCF with ECF. In an already completed international randomized phase II comparison of TC versus TCF (TAX-325), the three-drug combination proved significantly more active (RR 54% versus 32% with TC, among patients treated per protocol). Time to progression was also longer for TCF. Gastrointestinal (but not hematological) toxicity was less with TC. TCF was chosen for ongoing phase III comparison against a control 5-FU/cisplatin arm. It is possible that data from these randomized studies will confirm the value of docetaxel-based chemotherapy in advanced gastric cancer and that docetaxel combinations will also be effective in the multidisciplinary efforts to cure earlier stage cancer.

  • Antineoplastic Agents, Phytogenic/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
  • Cisplatin/administration & dosage
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Europe
  • Fluorouracil/administration & dosage
  • Humans
  • Multicenter Studies as Topic
  • Paclitaxel/administration & dosage/analogs & derivatives
  • Research Design
  • Stomach Neoplasms/drug therapy
  • Taxoids
  • Treatment Outcome
Citation (ISO format)
ROTH, Arnaud, AJANI, J. Docetaxel-based chemotherapy in the treatment of gastric cancer. In: Annals of oncology, 2003, vol. 14 Suppl 2, p. ii41–44. doi: 10.1093/annonc/mdg728
Main files (1)
Article (Published version)
ISSN of the journal0923-7534

Technical informations

Creation01/14/2015 4:20:00 PM
First validation01/14/2015 4:20:00 PM
Update time03/14/2023 10:42:02 PM
Status update03/14/2023 10:42:01 PM
Last indexation01/16/2024 3:57:07 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack